{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:41Z","timestamp":1787026481113,"version":"build-2736575974"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01112","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:34:57Z","timestamp":1591835697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Janne Tegder","family":"Martinsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Damsgaard","family":"Gunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Falkesgaard","family":"H\u00f8jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Schmeltz","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1126\/science.1165706","article-title":"The challenge of finding a cure for HIV infection","volume":"323","author":"Richman","year":"2009","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.immuni.2012.08.010","article-title":"Redefining the viral reservoirs that prevent HIV-1 eradication","volume":"37","author":"Eisele","year":"2012","journal-title":"Immunity."},{"key":"B3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev.immunol.18.1.665","article-title":"Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy","volume":"18","author":"Pierson","year":"2000","journal-title":"Annu Rev Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature06246","article-title":"Recognition of microorganisms and activation of the immune response","volume":"449","author":"Medzhitov","year":"2007","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int Rev Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and Non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses."},{"key":"B10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000086657","article-title":"TLR signalling and the function of dendritic cells","volume":"86","author":"Hemmi","year":"2005","journal-title":"Chem Immunol Allergy."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nri1246","article-title":"Dendritic-cell control of pathogen-driven T-cell polarization","volume":"3","author":"Kapsenberg","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1365-2567.2003.01563.x","article-title":"Distribution of toll-like receptor 1 and toll-like receptor 2 in human lymphoid tissue","volume":"108","author":"Ochoa","year":"2003","journal-title":"Immunology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell."},{"key":"B15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nat Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Adv Drug Deliv Rev."},{"key":"B17","volume-title":"Toll Like Receptors (TLRs) and Innate Immunity","author":"Akira","year":"2008"},{"key":"B18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3389\/fimmu.2017.01075","article-title":"The toll for trafficking: toll-like receptor 7 delivery to the endosome","volume":"8","author":"Petes","year":"2017","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/08830185.2016.1261318","article-title":"Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells","volume":"36","author":"Tartey","year":"2017","journal-title":"Int Rev Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fimmu.2014.00386","article-title":"TLR-dependent human mucosal epithelial cell responses to microbial pathogens","volume":"5","author":"McClure","year":"2014","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"24192","DOI":"10.1074\/jbc.M109.023044","article-title":"MyD88 adapter-like (Mal)\/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses","volume":"284","author":"Verstak","year":"2009","journal-title":"J Biol Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3389\/fimmu.2019.02450","article-title":"Targeting cellular and tissue HIV reservoirs with toll-like receptor agonists","volume":"10","author":"Macedo","year":"2019","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/ni.3157","article-title":"Innate immunity against HIV-1 infection","volume":"16","author":"Altfeld","year":"2015","journal-title":"Nat Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s00018-019-03156-8","article-title":"Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs","volume":"76","author":"Sadowski","year":"2019","journal-title":"Cell Mol Life Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: Shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"Sogaard","year":"2015","journal-title":"PLoS Pathog."},{"key":"B34","doi-asserted-by":"publisher","first-page":"a006916","DOI":"10.1101\/cshperspect.a006916","article-title":"Transcriptional and posttranscriptional regulation of HIV-1 gene expression","volume":"2","author":"Karn","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV."},{"key":"B37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.imlet.2018.02.004","article-title":"The role of latency reversal agents in the cure of HIV: a review of current data","volume":"196","author":"Bashiri","year":"2018","journal-title":"Immunol Lett."},{"key":"B38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/088922204323087741","article-title":"Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents","volume":"20","author":"Kulkosky","year":"2004","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Gutierrez","year":"2016","journal-title":"AIDS."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV."},{"key":"B41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1742-4690-8-80","article-title":"Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells","volume":"8","author":"Saleh","year":"2011","journal-title":"Retrovirology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1172\/JCI98071","article-title":"HIV latency is reversed by ACSS2-driven histone crotonylation","volume":"128","author":"Jiang","year":"2018","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1073\/pnas.91.17.7942","article-title":"Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells","volume":"91","author":"Lisziewicz","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"B44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/00912709922007552","article-title":"Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects","volume":"39","author":"Sereni","year":"1999","journal-title":"J Clin Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.4049\/jimmunol.171.4.1621","article-title":"Was induction of HIV-1 through TLR9?","volume":"171","author":"Agrawal","year":"2003","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.4049\/jimmunol.170.10.5159","article-title":"Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication","volume":"170","author":"Equils","year":"2003","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-4690-10-119","article-title":"Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1\/2 stimulation","volume":"10","author":"Novis","year":"2013","journal-title":"Retrovirology."},{"key":"B49","article-title":"Pattern recognition receptor agonists induce HIV in ART suppressed HIV+ donor cells","author":"Kaur","year":"2018","journal-title":"CROI 2018"},{"key":"B50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.virol.2009.04.019","article-title":"TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells","volume":"389","author":"Thibault","year":"2009","journal-title":"Virology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1128\/JVI.02166-16","article-title":"Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy","author":"Tsai","year":"2017","journal-title":"J Virol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e01369","DOI":"10.1128\/AAC.01369-16","article-title":"TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells","volume":"61","author":"Bam","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1128\/JVI.00222-16","article-title":"A novel toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4+ T cells","volume":"90","author":"Offersen","year":"2016","journal-title":"J Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1600-0854.2009.00899.x","article-title":"How location governs toll-like receptor signaling","volume":"10","author":"Chaturvedi","year":"2009","journal-title":"Traffic."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.4049\/jimmunol.175.3.1551","article-title":"Direct stimulation of human T cells via TLR5 and TLR7\/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells","volume":"175","author":"Caron","year":"2005","journal-title":"J Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy","volume":"117","author":"Krieg","year":"2007","journal-title":"J Clin Invest."},{"key":"B57","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/nat.2015.0533","article-title":"Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703","volume":"25","author":"Schmidt","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.4049\/jimmunol.1003174","article-title":"TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-alpha","volume":"186","author":"Schlaepfer","year":"2011","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e122673","DOI":"10.1172\/jci.insight.122673","article-title":"Dual TLR2 and TLR7 agonists as HIV latency-reversing agents","volume":"3","author":"Macedo","year":"2018","journal-title":"JCI Insight."},{"key":"B60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coviro.2019.06.001","article-title":"A broad drug arsenal to attack a strenuous latent HIV reservoir","volume":"38","author":"Stoszko","year":"2019","journal-title":"Curr Opin Virol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12977-019-0494-x","article-title":"Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency","volume":"16","author":"Telwatte","year":"2019","journal-title":"Retrovirology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.vetimm.2008.05.001","article-title":"Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates","volume":"125","author":"Ketloy","year":"2008","journal-title":"Vet Immunol Immunopathol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2567.2011.03484.x","article-title":"Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation","volume":"134","author":"Gujer","year":"2011","journal-title":"Immunology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.20111171","article-title":"Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans","volume":"208","author":"Caskey","year":"2011","journal-title":"J Exp Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1016\/j.vaccine.2017.09.052","article-title":"Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system","volume":"35","author":"Cheng","year":"2017","journal-title":"Vaccine."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1172\/JCI99005","article-title":"TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs","volume":"128","author":"Cheng","year":"2018","journal-title":"J Clin Invest."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","article-title":"Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial","volume":"24","author":"Kyi","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.critrevonc.2014.12.002","article-title":"MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside","volume":"94","author":"Wittig","year":"2015","journal-title":"Crit Rev Oncol Hematol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"eaao4521","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci Transl Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e127717","DOI":"10.1172\/jci.insight.127717","article-title":"TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia","volume":"4","author":"Del Prete","year":"2019","journal-title":"JCI Insight."},{"key":"B71","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3389\/fimmu.2019.00725","article-title":"Poly-ICLC, a TLR3 agonist, induces transient innate immune responses in patients with treated hiv-infection: a randomized double-blinded placebo controlled trial","volume":"10","author":"Saxena","year":"2019","journal-title":"Front Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/2326-6066.CIR-14-0024","article-title":"Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial","volume":"2","author":"Salazar","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B73","doi-asserted-by":"crossref","DOI":"10.1016\/S2055-6640(20)31079-7","volume-title":"Vesatolimod (GS-9620) is Safe and Pharmacodynamically Active in HIV-Infected Individuals","author":"Riddler","year":"2019"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24-week toll-like receptor 9 agonist treatment in HIV type 1+ individuals","volume":"33","author":"Vibholm","year":"2019","journal-title":"AIDS."},{"key":"B76","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ebiom.2019.07.005","article-title":"TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes","volume":"45","author":"Schleimann","year":"2019","journal-title":"EBioMedicine."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3390\/v6041837","article-title":"HIV-1 latency in monocytes\/macrophages","volume":"6","author":"Kumar","year":"2014","journal-title":"Viruses."},{"key":"B78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12977-016-0323-4","article-title":"Are T cells the only HIV-1 reservoir?","volume":"13","author":"Kandathil","year":"2016","journal-title":"Retrovirology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1097\/QAD.0b013e3283303e04","article-title":"Persistent HIV RNA shedding in semen despite effective antiretroviral therapy","volume":"23","author":"Sheth","year":"2009","journal-title":"AIDS."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/infdis\/jit308","article-title":"The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence","volume":"208","author":"Yukl","year":"2013","journal-title":"J Infect Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/rmv.1772","article-title":"The lungs as anatomical reservoirs of HIV infection","volume":"24","author":"Costiniuk","year":"2014","journal-title":"Rev Med Virol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1126\/science.aab2749","article-title":"Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection","volume":"350","author":"Sewald","year":"2015","journal-title":"Science."},{"key":"B83","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41564-018-0335-z","article-title":"HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy","volume":"4","author":"Ganor","year":"2019","journal-title":"Nat Microbiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fcimb.2019.00362","article-title":"Microglial cells: the main HIV-1 reservoir in the brain","volume":"9","author":"Wallet","year":"2019","journal-title":"Front Cell Infect Microbiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/ITT.S61292","article-title":"Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment","volume":"4","author":"Rajasekaran","year":"2015","journal-title":"Immunotargets Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1128\/microbiolspec.MCHD-0040-2016","article-title":"Toll-Like Receptor Signaling and Its Inducible Proteins","author":"Satoh","year":"2016","journal-title":"Microbiol Spectr."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J Exp Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fphar.2018.00642","article-title":"Molecular mechanisms of t cells activation by dendritic cells in autoimmune diseases","volume":"9","author":"Tai","year":"2018","journal-title":"Front Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B90","volume-title":"TLR Agonists and Latency Reversal: Can They Both Shock and Kill?","author":"Tolstrup","year":"2018"},{"key":"B91","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J Clin Invest."},{"key":"B92","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/mi.2017.59","article-title":"The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon","volume":"11","author":"Krarup","year":"2018","journal-title":"Mucosal Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e01163","DOI":"10.1128\/AAC.01163-19","article-title":"PD-1 Blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy","volume":"63","author":"Bekerman","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B95","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1084\/jem.169.2.549","article-title":"Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes","volume":"169","author":"Cassatella","year":"1989","journal-title":"J Exp Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e12705","DOI":"10.1111\/sji.12705","article-title":"The yin-yang of the interaction between myelomonocytic cells and NK cells","volume":"88","author":"Molgora","year":"2018","journal-title":"Scand J Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1097\/QAD.0000000000001645","article-title":"Natural killer cells in HIV-1 infection and therapy","volume":"31","author":"Mikulak","year":"2017","journal-title":"AIDS."},{"key":"B98","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1128\/JVI.03309-13","article-title":"Toll-like receptor 7\/8 (TLR7\/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques","volume":"88","author":"Moody","year":"2014","journal-title":"J Virol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e01844","DOI":"10.1128\/JVI.01844-16","article-title":"Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5\u03b1 Restrictive Macaques","volume":"91","author":"Kasturi","year":"2017","journal-title":"J Virol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1086\/653112","article-title":"Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial","volume":"51","author":"Sogaard","year":"2010","journal-title":"Clinical Infectious Diseases."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e62074","DOI":"10.1371\/journal.pone.0062074","article-title":"Administration of a toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients","volume":"8","author":"Winckelmann","year":"2013","journal-title":"PLoS ONE."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell."},{"key":"B105","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science."},{"key":"B106","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood."},{"key":"B109","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1756287215597647","article-title":"Targeting PD-1\/PD-L1 in the treatment of metastatic renal cell carcinoma","volume":"7","author":"Weinstock","year":"2015","journal-title":"Ther Adv Urol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/PPO.0000000000000299","article-title":"Clinical Development of PD-1 in Advanced Melanoma","volume":"24","author":"Munhoz","year":"2018","journal-title":"Cancer J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 Blockade in Cancer Immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e122940","DOI":"10.1172\/jci.insight.122940","article-title":"Combination anti-PD-1 antiretroviral therapy provides therapeutic benefit against SIV","volume":"3","author":"Mylvaganam","year":"2018","journal-title":"JCI Insight."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:07:59Z","timestamp":1616173679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":113,"alternative-id":["10.3389\/fimmu.2020.01112"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01112","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"article-number":"1112"}}